<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895268</url>
  </required_header>
  <id_info>
    <org_study_id>PEP02-03</org_study_id>
    <nct_id>NCT03895268</nct_id>
  </id_info>
  <brief_title>Influenza A+B Test Kit Performance Study</brief_title>
  <official_title>Prospective In Vitro Diagnostic Clinical Performance Study for an Influenza A+B Point-of-Care Test Kit on Patients Exhibiting Influenza-like Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa BioTech Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prince of Wales Hospital, Shatin, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanwa BioTech Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective clinical study on the performance of an Influenza A+B rapid test kit. The main
      goal is to establish the sensitivity and specificity (i.e. how accurate the test is) when
      compared to a gold standard.

      Option of participating in this clinical study will be presented to patients displaying
      influenza-like illness. Informed consent will be collected from patients or patient's next of
      kin/guardian before samples (nasopharyngeal swab) are taken from the patient.

      Nasopharyngeal swabs are tested using both the investigational test kit and a predicate
      fluorescence immunoassay test kit. All samples will be tested using a molecular-based PCR
      test kit as a confirmatory test.

      The results will be analysed statistically and the performance of the Influenza A+B test kit
      can be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza is an acute respiratory infection caused by influenza viruses which circulate in
      all parts of the world. Influenza viruses are causative agents of highly contagious, acute,
      viral infections of the respiratory tract. Influenza viruses are immunologically diverse,
      single-stranded RNA viruses.

      There are 3 types of seasonal influenza viruses, types A, B, and C. Influenza A+B and B
      viruses circulate and cause outbreaks and epidemics. Influenza type C virus is detected much
      less frequently and usually causes mild infections, thus presents less significant public
      health implications.

      Seasonal influenza has an incubation period of approximately 2 days and is characterized by a
      sudden onset of fever, cough, headache, muscle and joint pain, severe malaise, sore throat
      and a runny nose. Most people recover within a week without requiring medical attention but
      influenza can cause severe illness or death especially in vulnerable populations such as
      children, pregnant women and elderlies. Seasonal influenza causes public health concerns as
      it spreads easily, with rapid transmission in crowded areas including schools and nursing
      homes.

      Antiviral drugs for Influenza A and Influenza B are available in some countries and may
      reduce severe complications and deaths. Ideally these antiviral drugs need to be administered
      within 48 hours of onset of symptoms and hence rapid diagnosis of influenza in patients
      displaying influenza-like Illness can reduce the number of severe complications and deaths
      associated with influenza.

      Fluorescent Immunoassay is a biochemical technique used for detecting the binding of the
      &quot;detection&quot; antibody and the analyte molecule. The advantages of a fluorescent detection
      system have been known for many years. These include higher sensitivity detection of the
      analyte, simplified reagents and simpler assay designs. Several breakthroughs have occurred
      over the past few years that have enabled the implementation of a fluorescent based
      immunoassay system at the point of care.

      A modern fluorescent based immunoassay uses a fluorescent compound, which absorbs light or
      energy (excitation energy) at a specific wavelength and then emits light or energy at a
      different wavelength, as the detection reagent. The difference between the wavelength of the
      excitation light and the emission light is called the Stokes shift. The greater the shift or
      difference in the wavelength the less interference there will be by having the excitation
      light detected as part of the emission light. Recently many technical improvements have
      occurred that has enabled the implementation of a high sensitivity immunoassay system. These
      include the availability of narrow wavelength low cost light sources, newer more stable
      fluorophores that have very wide Stokes shifts, stable solid state light detectors and
      microprocessors to process and analyse the data from each test.

      When a fluorescent detection system is linked to a lateral flow assay and matched with a
      powerful analyser like the ALiA Diagnostic Platform, the result is improved assay
      performance, the opportunity for walk away testing along with the elimination of
      misinterpretation often associated with visually-read point-of-care assays.

      Influenza A and Influenza B affect all population, any patients of age 18 or above displaying
      symptoms of respiratory infection will be included as potential participants.

      There will be no restriction on the ethnicity of patients but the majority of patients to be
      recruited are expected to be of Asian origin as the clinical trial is based in Hong Kong.
      However, it has been proved that Influenza strains do not vary / have minimal variation in
      human of different ethnicity.

      Study Design:

      Option for participating in this clinical study will be presented to patients satisfying the
      patient selection criteria. Informed consent will be collected from patients before samples
      (nasopharyngeal swab) are taken.

      Nasopharyngeal swabs are tested using the investigational products, a predicate fluorescence
      immunoassay test, and a molecular-based PCR test will be used as the gold standard.

      Study Duration:

      Considering the seasonal nature of the disease, duration of the study is estimated to be
      approximately 24 months from inclusion of first subject to the day of final analysis of the
      last subject's sample.

      Study Hypothesis:

      When compared to PCR:

      The positive percent agreement (sensitivity) for the investigational product when testing for
      influenza A and influenza B should be at least 85 percent with a lower bound of the 95
      percent confidence interval that is greater than or equal to 70 percent.

      The negative percent agreement (specificity) for the Investigational Product when testing for
      influenza A is at least 90 percent with a lower bound of the 95 percent confidence interval
      that is greater than or equal to 80 percent.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical sensitivity and clinical specificity of the investigational devices</measure>
    <time_frame>2 Years</time_frame>
    <description>Establish clinical sensitivity and specificity of investigational devices by comparing with PCR results using fresh and frozen sample</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Influenza Type A</condition>
  <condition>Influenza Type B</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALiA Analyser</intervention_name>
    <description>NPS specimens shall be tested with the investigational device</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Influenza A+B Test Kit</intervention_name>
    <description>NPS specimens shall be tested with the investigational device</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The study will use nasopharyngeal swab specimens taken from hospitalized subjects displaying
      influenza-like illness.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Influenza A and Influenza B affect all population, any patients of age 18 or above
        displaying symptoms of respiratory infection will be included as potential participants.

        There will be no restriction on the ethnicity of patients but the majority of patients to
        be recruited are expected to be of Asian origin as the clinical trial is based in Hong
        Kong. However, it has been proved that Influenza strains do not vary / have minimal
        variation in human of different ethnicity.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is having NPA collected by the hospital as routine testing

          -  Patient or patient's next of kin/guardian is willing and able to give informed consent
             for participation in the trial.

          -  Patients presented with influenza-like illness, i.e. fever and cough, with onset of
             illness within 7 days of hospital admission

          -  Male or Female, 18 years of age or above.

        Exclusion Criteria:

        â€¢ Have had influenza-specific treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul KS Chan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Wong, Dr.</last_name>
    <phone>+852 2698 7970</phone>
    <email>veronica@sanwabiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

